Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma
about
Proteoglycan form and function: A comprehensive nomenclature of proteoglycansThe Role of NG2 Proteoglycan in GliomaDiversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsetsDynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastomaTheranostic impact of NG2/CSPG4 proteoglycan in cancerStonin1 mediates endocytosis of the proteoglycan NG2 and regulates focal adhesion dynamics and cell motility.Manganese-containing Prussian blue nanoparticles for imaging of pediatric brain tumors.Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumorsCSPG4: a prototype oncoantigen for translational immunotherapy studies.Novel points of attack for targeted cancer therapy.Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma.Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors.Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.NG2 proteoglycan-dependent recruitment of tumor macrophages promotes pericyte-endothelial cell interactions required for brain tumor vascularization.NG2 Proteoglycan-Dependent Contributions of Pericytes and Macrophages to Brain Tumor Vascularization and Progression.Proteoglycans and their roles in brain cancer.NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion.NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survivalNG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma.Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.Glycosaminoglycans: key players in cancer cell biology and treatment.Therapeutic potential and challenges of natural killer cells in treatment of solid tumorsChondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.NG2 Proteoglycan Enhances Brain Tumor Progression by Promoting Beta-1 Integrin Activation in both Cis and Trans Orientations.Progenitor/Stem Cell Markers in Brain Adjacent to Glioblastoma: GD3 Ganglioside and NG2 Proteoglycan Expression.Role of NG2 proteoglycan in macrophage recruitment to brain tumors and sites of CNS demyelination.Decline in arylsulfatase B leads to increased invasiveness of melanoma cells.Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft tissue sarcoma growth depend on tumor developmental stage.Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties in histologically normal surgical margins.CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas
P2860
Q21710680-70263574-035F-4579-A034-D17E1BD5113DQ26767702-8C0B2614-A6A5-4908-8B35-49F8CCDF7E10Q27334435-F36E2584-AFD8-4046-9E18-28CE9CC8849DQ27344690-8A995ECA-60EE-4E5D-AF2F-DBC515521EFAQ28085331-D6A3111D-2886-4179-BFDC-F25F4218F429Q30667566-ECF91741-1E47-4FB9-B21F-3D780D7213B4Q33706579-7D2F0902-E6C0-4C4E-8CE5-6534869F9DCBQ33763660-3E91DB3C-AA64-4571-8CE6-4064779C3A37Q33862585-03E09CCF-F3BC-4866-8532-A463D1430CB9Q35023279-74D64F5F-A2B4-4644-9CEB-C996A98AA3AEQ35257150-803584FA-659F-4907-B4DD-C125ACB2CD11Q35599740-C1408B2C-7E88-4794-8B51-622A73526269Q35692312-C4C9B217-636C-4B4D-8B41-7665EC1B97D6Q35799099-E824140A-E4DB-471B-A5EE-6851733FA7CBQ36552576-BC8A6FC2-59AF-4E8D-B2ED-CE619D507F2CQ36816444-B4C63F47-DBEA-40F6-82DA-9BFC4170FEF0Q36851314-11985BD2-0B16-4908-A939-540AB3A0C26EQ36916334-168648E0-2BF0-46D9-AA66-E1CBD1135B43Q37299271-1939B118-9F3E-4657-8AA5-792FCBC4F03FQ37417578-3CEC8F8F-CCB1-49EC-9B2A-9718B6A047B7Q37470684-59B046D6-25ED-4633-8AA4-96657763EA47Q37946449-3343A545-D1BF-4DBB-98D7-EFFB0AD4BAE7Q37983930-4BDC0D71-A0B8-484C-819B-735BECBAF843Q38478878-BC6BC40C-C774-47C9-9538-AAAC6D7C2E8FQ38550541-87851B87-7732-41CC-A402-34286820DCDAQ38941698-8B890C7B-0821-4E20-B29E-9F02C0D36768Q38987239-972BC7BA-9F8A-4A72-9D0D-0F27BA563D68Q39020795-5B5D1D90-4926-4C3B-BBD3-00821C8A665DQ39210909-EA02B92B-1D5E-40B1-B5F3-923F169A0BE2Q40080387-979BFF73-9130-4A14-8D84-757C96040C7AQ41786397-6AC491FB-1BC7-4330-BE5C-65482AB9A1DFQ42021143-49B0A459-00D0-41E7-B544-828DAEDC643AQ47340171-A26134EC-BF50-46C4-89B3-B52BA60D5D08Q47555734-A7E63749-4021-4222-9D75-E35869D11E94Q47748770-4DF50001-C000-42E6-B6F9-E71D186CB0D1Q48413806-E3C52994-A134-4E36-A34A-98221588916BQ50918966-E9E95396-6E2F-454A-8688-A12D473EF8BBQ58745277-1428EAF4-AF45-4010-8E74-DFD553949981
P2860
Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Targeting the NG2/CSPG4 proteo ...... cal models of GBM and melanoma
@ast
Targeting the NG2/CSPG4 proteo ...... cal models of GBM and melanoma
@en
Targeting the NG2/CSPG4 proteo ...... cal models of GBM and melanoma
@nl
type
label
Targeting the NG2/CSPG4 proteo ...... cal models of GBM and melanoma
@ast
Targeting the NG2/CSPG4 proteo ...... cal models of GBM and melanoma
@en
Targeting the NG2/CSPG4 proteo ...... cal models of GBM and melanoma
@nl
prefLabel
Targeting the NG2/CSPG4 proteo ...... cal models of GBM and melanoma
@ast
Targeting the NG2/CSPG4 proteo ...... cal models of GBM and melanoma
@en
Targeting the NG2/CSPG4 proteo ...... cal models of GBM and melanoma
@nl
P2093
P2860
P50
P1433
P1476
Targeting the NG2/CSPG4 proteo ...... cal models of GBM and melanoma
@en
P2093
Cecilie Brekke Rygh
Heike Immervoll
Hrvoje Miletic
Jesús Planagumà
Justyna Kmiecik
Kai Ove Skaftnesmo
Martha Chekenya
Per Øyvind Enger
P2860
P304
P356
10.1371/JOURNAL.PONE.0023062
P407
P577
2011-01-01T00:00:00Z